Table 1 Recent patent applications in protein expression
From: Patents
Patent # | Subject | Assignee | Inventor(s) | Priority application date | Publication date |
|---|---|---|---|---|---|
US 20040151736 | A new subcellular protein expressed from a Francisella tularensis–infected mammal subculture growing in synthetic salts medium of weak acidity; useful as a vaccine candidate against infectious agents, e.g., bacteria, viruses or parasites. | Canada Ministry of National Defence (Ottawa, ON, Canada); Berger BJ; Cherwonogrodzky JW; Sikora CA | Berger BJ, Cherwonogrodzky JW, Sikora, CA | 1/24/2003 | 8/5/2004 |
EP 1441035 | Preparing profiles of differential protein expression, useful for comparing proteomes, for example, to identify proteins expressed at a higher or lower level after a change in conditions. | BioVendor Laboratory Medicine (Brno, Czech Republic) | Ruzicka V | 1/23/2003 | 7/28/2004 |
WO 200461458 | A method for detecting multidrug resistance or multidrug resistance potential in a test neoplastic cell by measuring heat shock cognate 70 protein level in the cell, and comparing the level of protein expression in the test cell and a nonresistant neoplastic cell. | Aurelium BioPharma (Montreal, PQ, Canada) | Bonneau A, Dallaire F, Georges E, Serfass L | 1/3/2003 | 7/22/2004 |
JP 2004201648 | A gene-screening method involving transducing a test gene into a cell, expressing protein on the cell surface, and analyzing the gene-encoding protein expressed on the surface of the cell, which is coupled with a magnetic particle fixed to a ligand. | Chisso Corp. (Tokyo) | – | 12/26/2002 | 7/22/2004 |
WO 200459003 | A method for preparing a carrier for the detection of analytes, by the synthesis of receptors on a surface and the introduction of hapten groups to allow for monitoring the quality of synthesis; useful especially as DNA chips for analysis, including gene expression studies, target validation (re)sequencing and genome or proteome analysis. | Febit (Mannheim, Germany) | Beier M | 5/7/2003 | 7/15/2004 |
WO 200458157 | A method of protecting an animal against a cancer, comprising administering a yeast vehicle and a fusion protein expressed by the yeast vehicle comprising at least one cancer antigen, and a linked peptide or yeast protein that stabilizes the expression of the fusion protein or prevents its post-translational modification. | Bellgrau D; Franzusoff A; GlobeImmune (Aurora, CO, USA) | Bellgrau D, Franzusoff A | 12/16/2002 | 7/15/2004 |
WO 200456986 | Providing a cell with a protein expression unit, by providing a nucleic acid comprising the unit with a nucleic acid encoding a binding site for a member of a chromatin modification system for rendering chromatin more accessible for transcription. | ChromaGenics (Amsterdam, the Netherlands) | Kwaks THJ, Otee AP, Sewalt RGAB | 1/13/2003 | 7/8/2004 |
WO 200457033 | Determining whether a molecule affects the function or activity of a glucan synthase pathway in a Saccharomyces cerevisiae cell by determining a change in the RNA expression or protein expression in the cell of at least one target polynucleotide. | Rosetta Inpharmatics (Seattle, WA, USA) | Phillips JW | 12/19/2002 | 7/8/2004 |
CA 2449417 | A method for identifying compounds for regulating expression of a ubiquitinylation pathway component protein involved in cardiac dysfunction, comprising contacting a test compound with a cell population expressing the protein of interest, determining the expression of the desired protein and identifying those test compounds that modulate the expression of the desired protein. | Procter & Gamble (Cincinnati, OH, USA) | Doersen CW, Kawamoto RM | 12/4/2002 | 6/4/2004 |
RU 2229518 | A plasmid, pBMC-nef(A)m-1, comprising the nef gene of human immunodeficiency virus type I, subtype A. The plasmid is designed for expression of protein NEF and can be used for immunization against human immunodeficiency virus. | BioMed Centre (St. Petersburg, Russia) | Klimov NA, Kozlov AP, Masharskii AE, Murashev BV, Murasheva IV, Polyakov MS, Romanovich AE | 5/22/2003 | 5/27/2004 |
